Clinical trials: Dementia of Alzheimer Type
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Dementia
Development of NIC5-15 in the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
- Trial name
- NCT00470418
- Testing
- NIC5-15
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Dementia, Alzheimer Type, Mild Cognitive Impairment
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits.
- Conditions
- Dementia, Alzheimer Type, Mild Cognitive Impairment, Cardiac Amyloidosis
- Trial name
- NCT07154394
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital, Essen
Alzheimer Disease, Cognitive Impairment
Multi-Center Study of Sensory Stimulation to Improve Brain Function
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
- Trial name
- Overture (NCT03556280)
- Testing
- GammaSense Stimulation System (Active Settings)
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cognito Therapeutics, Inc.
Dementia, Alzheimer Type
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
A recent study (Saltmarche et al., 21017) examined the effects of photobiomodulation (PBM), a kind of light therapy that uses red or near-infrared light to heal and protect tissue that has either been injured, is degenerating, or…
- Trial name
- PBM Dementia (NCT03160027)
- Testing
- Vielight Neuro Gamma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Dementia of Alzheimer Type
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
This is a study to evaluate the impact of returning research results that indicate a five-year risk estimate of Alzheimer disease dementia to participants without memory or thinking problems of the Knight Alzheimer Disease…
- Trial name
- WeSHARE (NCT04699786)
- Testing
- Arm A , Arm B, Arm C, & Arm D
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Washington University School of Medicine
Hearing Loss, Sensorineural, Dementia of Alzheimer Type
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild…
- Conditions
- Hearing Loss, Sensorineural, Dementia of Alzheimer Type, Amnestic Mild Cognitive Impairment
- Trial name
- NCT04240561
- Testing
- High level of signal manipulation, Low level of signal manipulation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Alzheimer's Type Dementia, Cognitive Decline
The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients
This research study is developed on an experimental design with randomized controlled intervention were participated 135 subjects with AD including 45 of the control group.
- Conditions
- Alzheimer's Type Dementia, Cognitive Decline, Postural; Strain
- Trial name
- GPR (NCT03732053)
- Testing
- GPR Intervention Research group
- Volunteers
- 135 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Alzheimer Disease, Dementia of Alzheimer Type
Couples Lived Experience
This is a longitudinal study with regular quantitative assessments of all participants every six months for 3 years. The quantitative portion of the study will recruit couples, consisting of individuals over the age of 65 who are…
- Trial name
- NCT04863495
- Where
- 2 sites in United States
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842816
- Testing
- ST101
- Where
- 30 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimer's Disease
CPC-201 Alzheimer's Disease Type Dementia: PET Study
The purpose of this study is to compare the effect of low and high dose CPC-201 on brain function including cerebral acetylcholinesterase (AChE) activity measured by positron emission tomography (PET).
- Trial name
- NCT02860065
- Testing
- CPC-201, Positron emission tomography (PET)
- Where
- United States
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Dementia, Alzheimer Type, Problem Behavior
Home Evaluation of Exit Barriers in Wandering
Main hypothesis. Floor and door visual exit barriers will decrease exit-seeking wandering (exit door approaches) proximal to exit doorways by persons with dementia who wander.
- Trial name
- HEEBW (NCT00997425)
- Testing
- Door cover/Floor cover
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- US Department of Veterans Affairs
Alzheimer's Disease
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Open-label treatment with MPC-7869 for participants in a previous randomized study.
- Trial name
- NCT00380276
- Testing
- MPC-7869
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Myrexis Inc.
Alzheimer Disease
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.
A program that combines high intensity aerobic exercise (<85% of Heart Rate Reserve) with resistance, progressive and moderate intensity intervals, carried out in primary care, is effective in terms of a smaller increase in…
- Trial name
- EFA-P (NCT02195596)
- Testing
- High intensity aerobic exercise+strength, Low intensity aerobic exercise+strength
- Where
- 3 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Basque Health Service
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Dementia, Mixed, Dementia, Vascular
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.
- Conditions
- Dementia, Mixed, Dementia, Vascular, Dementia of Alzheimer Type, Cognitive Decline
- Trial name
- STAREE-Mind (NCT05586750)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- 2 sites in Australia
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Monash University
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Alzheimer's Disease, Dementia, Alzheimer Type
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
- Trial name
- NCT00099242
- Testing
- rivastigmine transdermal patch
- Where
- 75 sites in United States, Chile and 19 more
- Volunteers
- 1,040 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Dementia, Vascular
Factors Associated With Mortality, Morbidity and Prognosis in Dementia Patients
Dementia; It is a chronic syndrome characterized by a general and progressive deterioration in cognition, including memory, orientation, language, and comprehension.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia of Alzheimer Type
- Trial name
- NCT05052450
- Testing
- Observational
- Volunteers
- 1,000 people
- Sponsor
- Gulhane Training and Research Hospital